The role of DNase-I in SLE received attention when it was discovered that the presence of a DNase-I inhibitor correlated with levels of nuclear autoantibodies [1] and that SLE patients had decreased serum nuclease activity [4]. Here, DNASE1L3 is linked to systemic lupus erythematosus.